A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated

A Dose-Finding Study of CpG 7909 in Previously Treated Chronic Lymphocytic Leukemia

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00233506

Enrollment

Registered

2005-10-05

Start date

2004-07-31

Completion date

2011-06-30

Last updated

2017-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Lymphocytic Leukemia

Keywords

CpG 7909, CLL

Brief summary

* CpG has the potential to stimulate the immune system * this study will evaluate the safety of CpG given sub-q or IV * purpose is to measure biological changes in CLL cells after receiving CpG

Interventions

DRUGCpG 7909

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of CLL * CLL previously treated * Hemoglobin \>/= 10 * Platelets \>/= 50,000 * Neutrophils \>= 1,000 -

Exclusion criteria

* patients with brain mets * patients with autoimmune disease * patients on corticosteroids or immunosuppressants * patients with uncontrolled intercurrent illness * pregnant women * HIV patients receiving combination anti-retroviral therapy

Design outcomes

Primary

Measure	Time frame
maximum tolerated dose	at study completion

Secondary

Measure	Time frame
response	at end of treatment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026